Clot-Busting drugs may cut death risk in lung clot patients
NCT ID NCT07374978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving clot-busting drugs (thrombolysis) to people with a serious but not immediately life-threatening type of lung clot (pulmonary embolism) and a low risk of bleeding could lower their chance of dying within 30 days. The study included 100 patients and tracked deaths and major bleeding events. The goal was to see if the benefits of breaking up the clot outweigh the risks of bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jul 2023
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with intermediate high risk pulmonary embolism diagnosed according to clinical probability using revised Geneva Score and diagnosis confirmed by echocardiography and Troponin I or T level and CT pulmonary angiography Exclusion Criteria: * o High risk PE * Intermediate low risk PE * low risk PE * Patients with left ventricular systolic dysfunction (ischemic or non-ischemic etiology) * Patients with chronic lung diseases (obstructive or restrictive) * Patients with contraindications to thrombolysis: * History of haemorrhagic stroke or stroke of unknown origin * Ischaemic stroke in previous 6 months * Central nervous system neoplasm * Major trauma, surgery, or head injury in previous 3 weeks * Bleeding diathesis (known inherited bleeding disorder, for example, haemophilia, platelet count \<50,000/uL) * Active bleeding * Transient ischaemic attack in previous 6 months * Oral anticoagulation * Pregnancy or first post-partum week * Non-compressible puncture sites * Traumatic resuscitation * Severe hypertension (systolic BP \>180 mmHg) * Advanced liver disease * Infective endocarditis * Active Peptic ulcer * Patients who develop hypotension or bradycardia or allergic reaction requiring discontinuation of Streptokinase infusion. * Patients with HAS-BLED score greater than or equals 3 (high bleeding risk for thrombolysis)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary embolism subacute massive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
Cairo, Abbassia, 00202, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.